AC
BMY icon

Apex Capital’s Bristol-Myers Squibb BMY Stock Holding History

Apex Capital’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-250,000
Closed -$14.8M – 41
2015
Q3 		$14.8M Buy
+250,000
New +$15.9M 1.41% 32

Other funds holding BMY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Apex Capital's BMY Position: Q4 2015 in Review

Apex Capital sold out of Bristol-Myers Squibb (BMY) in Q4 2015, closing a stake of 250,000 shares — an estimated $14.8M sold.

Apex Capital first reported a position in BMY in Q3 2015 and held it in 1 quarter. The position peaked at $14.8M in Q3 2015. 1,535 funds tracked by Wall St. Rank hold BMY as of Q4 2015.

  • Apex Capital reported no remaining Bristol-Myers Squibb position as of Q4 2015 after selling out during the quarter.
  • Apex Capital sold 250,000 Bristol-Myers Squibb shares in Q4 2015, an estimated $14.8M.
  • Apex Capital first reported a position in Bristol-Myers Squibb in Q3 2015 and held it in 1 quarter.
  • Apex Capital's Bristol-Myers Squibb position peaked at $14.8M in Q3 2015.
  • 1,535 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2015.

Based on Apex Capital's 13F filing for Q4 2015, filed 16 Feb 2016.